Emergent BioSolutions Statistics
Share Statistics
Emergent BioSolutions has 54.18M shares outstanding. The number of shares has increased by 3.79% in one year.
| Shares Outstanding | 54.18M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.3% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 52.75M |
| Failed to Deliver (FTD) Shares | 53.58K |
| FTD / Avg. Volume | 4.24% |
Short Selling Information
The latest short interest is 6.94M, so 12.8% of the outstanding shares have been sold short.
| Short Interest | 6.94M |
| Short % of Shares Out | 12.8% |
| Short % of Float | 13.32% |
| Short Ratio (days to cover) | 6.01 |
Valuation Ratios
The PE ratio is -0.16 and the forward PE ratio is 3.64.
| PE Ratio | -0.16 |
| Forward PE | 3.64 |
| PS Ratio | 0.12 |
| Forward PS | 0.5 |
| PB Ratio | 0.19 |
| P/FCF Ratio | -0.48 |
| PEG Ratio | n/a |
Enterprise Valuation
Emergent BioSolutions Inc. has an Enterprise Value (EV) of 888.68M.
| EV / Earnings | -1.17 |
| EV / Sales | 0.85 |
| EV / EBITDA | -1.76 |
| EV / EBIT | -1.22 |
| EV / FCF | -3.45 |
Financial Position
The company has a current ratio of 1.04, with a Debt / Equity ratio of 1.32.
| Current Ratio | 1.04 |
| Quick Ratio | 0.54 |
| Debt / Equity | 1.32 |
| Total Debt / Capitalization | 56.99 |
| Cash Flow / Debt | -0.24 |
| Interest Coverage | -8.26 |
Financial Efficiency
Return on equity (ROE) is -1.17% and return on capital (ROIC) is -50.05%.
| Return on Equity (ROE) | -1.17% |
| Return on Assets (ROA) | -0.42% |
| Return on Capital (ROIC) | -50.05% |
| Revenue Per Employee | 655.81K |
| Profits Per Employee | -475.31K |
| Employee Count | 1.60K |
| Asset Turnover | 0.58 |
| Inventory Turnover | 2.14 |
Taxes
| Income Tax | 29.30M |
| Effective Tax Rate | -0.04 |
Stock Price Statistics
The stock price has increased by 361.58% in the last 52 weeks. The beta is 1.57, so Emergent BioSolutions 's price volatility has been higher than the market average.
| Beta | 1.57 |
| 52-Week Price Change | 361.58% |
| 50-Day Moving Average | 9.32 |
| 200-Day Moving Average | 7.61 |
| Relative Strength Index (RSI) | 50.39 |
| Average Volume (20 Days) | 1.26M |
Income Statement
In the last 12 months, Emergent BioSolutions had revenue of 1.05B and earned -760.50M in profits. Earnings per share was -14.85.
| Revenue | 1.05B |
| Gross Profit | 343.90M |
| Operating Income | -726.40M |
| Net Income | -760.50M |
| EBITDA | -505.30M |
| EBIT | -726.40M |
| Earnings Per Share (EPS) | -14.85 |
Balance Sheet
The company has 111.70M in cash and 860.20M in debt, giving a net cash position of -748.50M.
| Cash & Cash Equivalents | 111.70M |
| Total Debt | 860.20M |
| Net Cash | -748.50M |
| Retained Earnings | -21.80M |
| Total Assets | 1.48B |
| Working Capital | 431.50M |
Cash Flow
In the last 12 months, operating cash flow was -206.30M and capital expenditures -51.60M, giving a free cash flow of -257.90M.
| Operating Cash Flow | -206.30M |
| Capital Expenditures | -51.60M |
| Free Cash Flow | -257.90M |
| FCF Per Share | -5.04 |
Margins
Gross margin is 32.77%, with operating and profit margins of -69.23% and -72.48%.
| Gross Margin | 32.77% |
| Operating Margin | -69.23% |
| Pretax Margin | -69.68% |
| Profit Margin | -72.48% |
| EBITDA Margin | -48.16% |
| EBIT Margin | -69.23% |
| FCF Margin | -24.58% |
Dividends & Yields
EBS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -158.48% |
| FCF Yield | -50.8% |
Analyst Forecast
The average price target for EBS is $15, which is 60.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 60.1% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 1.08 |
| Piotroski F-Score | 6 |